Merck, Moderna Detail Potential Skin Cancer Vaccine Progress

December 13, 2022

GENEVA – Shares of Merck and Moderna jumped early Tuesday after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots did well in a mid-stage study.

The drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had the tumors removed in surgery.

That combination was compared with Keytruda alone in a mid-stage clinical trial of 157 patients.

The patient group that took the potential vaccine and Keytruda saw a 44% reduction in the risk of death or the cancer returning, the companies said.

Merck and Moderna expect to start a phase 3 study of the combination next year. That’s generally the last and largest clinical study before a drug is submitted to regulators for approval.

The potential vaccine aims to train a patient’s immune system to recognize and respond specifically to mutations in their tumor. Keytruda, Merck’s top seller, primes the body’s immune system to detect and fight tumor cells.

Shares of Moderna jumped more than 8% in premarket trading, while Merck rose more than 2% and futures indexes increased slightly.


Good and healthy nutrition is connected with other concepts like environmental and economic sustainability for society as a whole and affordability and convenience for individual consumers.

Top Stories


A pregnant woman was driving in the HOV lane near Dallas.

General News

FALMOUTH, MA – The police in Falmouth have identified the victim in an accident involving a car plunging into the ocean on February 20, NBC10 Boston reported.

General News

NEW YORK – Meropi Kyriacou, the new Principal of The Cathedral School in Manhattan, was honored as The National Herald’s Educator of the Year.


Enter your email address to subscribe

Provide your email address to subscribe. For e.g. [email protected]

You may unsubscribe at any time using the link in our newsletter.